Quantum BioPharma reported total shareholders’ equity of $9.77 million as of September 30, 2026. That was a 91% increase from the end of 2025. Combined cash and digital assets reached $12.22 million. Operating expenses fell 32% in the first nine months of 2026.

The company is advancing its Phase 2 trial of Lucid-MS, a potential treatment for progressive multiple sclerosis. The U.S. Food and Drug Administration cleared the Investigational New Drug application in August 2026. Quantum has since signed a study start-up agreement with Thermo Fisher Scientific to implement the trial.